For example, there are large interindividual differences in the expression levels and catalytic activities of CYP enzymes in human liver. 5) Additionally, multiple isozymes of carboxylesterases exist in humans, and interindividual variations of the carboxylesterase activities have important clinical implications. 6 ) Recently, we have reported interindividual variations in the 2-hydroxylation (CYP3A4), sulfation, and glucuronidation of ethynylestradiol in human microsomes and cytosol. 7) On the other hand, intrinsic metabolic clearance (CL int ) is calculated as a ratio of V max to K m in order to predict in vivo drug disposition. [8] [9] [10] Sugiyama and colleagues 8, 9) proposed the prediction of in vivo metabolic clearance in experimental animals and humans from in vitro biochemical parameters such as hepatic metabolism and plasma protein binding, based on anatomically and physiologically realistic pharmacokinetic models. However, there are few reports on interindividual variations as well as enzymatic kinetics (V max and K m values) in other drug-metabolizing enzymes, including cytosolic enzymes such as dihydropyrimidine dehydrogenase (DPD) and N-acetyltransferase (NAT).
5-Fluorouracil has been one of the most widely used anticancer drugs, and it is well documented that there is wide individual variation in both the tumor response and host toxicity associated with 5-fluorouracil. 11) In addition, marked interindividual differences in the pharmacokinetic parameters of 5-fluorouracil have been reported.
12) The primary metabolic pathway of this drug is the reduction to 5,6-dihydroflurouracil by DPD present in a liver cytosol fraction. 13) After intravenous dosing to cancer patients, approximately 60-90% of the dose is excreted in urine within 24 h, primary as a-fluoro-b-alanine, 12) indicating that 5-fluorouracil is mainly eliminated by metabolism.
The major metabolic route of procainamide, a class I antiarrhythmic agent, is acetylation to N-acetylprocainamide, which is an active metabolite, and a wide variety in the amount of N-acetylprocainamide recovered after a dose of procainamide has been reported by different laboratories. Gibson et al. 14) reported 7 to 34% N-acetylprocainamide recovery in 24 h in normal volunteers after a single oral dose of procainamide, and Karlsson et al. 15) reported 6 to 53% recovery in 24 h in patients who were being given procainamide chronically.
As mentioned above, there are large interindividual differences in the pharmacokinetics of 5-fluorouracil and procainamide, which are mainly eliminated by metabolism. Therefore, we investigated the enzymatic kinetics and interindividual variability of the metabolism of 5-fluorouracil and procainamide in human liver cytosol. 16) Each liver specimen was homogenized with 3 volumes of 1.15% KCl using a Teflon-glass homogenizer. The homogenate was centrifuged at 10000ϫg for 20 min, and the supernatant was centrifuged at 105000ϫg for 60 min (4°C). The supernatant was used as the cytosol. Microsomes and cytosol from human liver and intestine were stored at Ϫ80°C until use. The protein concentrations of samples prepared in our laboratories were determined by the method of Lowry et al. 17) using bovine serum albumin as the standard.
MATERIALS AND METHODS

Materials
Assay for DPD Activity of 5-Fluorouracil The DPD activity of 5-fluorouracil was measured by the method of Kanamitsu et al. 13) with a minor modification. Briefly, the incubation mixture consisted of 2-100 mM [6] [7] [8] [9] [10] [11] [12] [13] [14] C] labeled 5-fluorouracil, liver cytosol (0.5 mg protein/ml), 0.25 mM NADPH, and 35 mM potassium phosphate buffer (pH 7.4) in a final volume of 250 ml. The reaction was started by adding NADPH and the mixture was incubated at 37°C for 15 min. The reaction was terminated by adding 60 ml of 2 M KOH. After adding 15 ml of 60% perchloric acid, the mixture was centrifuged at 12000ϫg for 2 min. 5-Fluorouacil and a-fluoro-b-alanine, which was formed by hydrolysis of 5-fluorodihydrouracil by adding 2 M KOH, were separated by thin-layer chromatography (place: Polygram CEL 300 PEI/UV 254 ; Machery-Nagel, Germany; solvent: t-butanol/ethyl acetate/ water, 4 : 3 : 2) and quantified by BAS2000 (Fujifilm, Tokyo, Japan).
Assay for Procainamide N-Acetyltransferase Activity The incubation mixture consisted of procainamide, liver cytosol (0.5 mg protein/ml), 1 mM acetyl CoA, and 100 mM Tris-HCl buffer (pH 7.4) in a final volume of 500 ml. Procainamide concentration was set at 2 mM, except for kinetic studies where the substrate concentrations varied from 0.2 to 20 mM. After preincubation at 37°C for 3 min, the reaction was started by adding procainamide and the mixture was incubated at 37°C for 15 min. The reaction was terminated by adding 200 ml of acetonitrile, and the mixture was centrifuged at 12000ϫg for 3 min. A 20 ml sample of the supernatant was injected into an HPLC, and the concentration of N-acetylprocainamide analyzed. The HPLC system consisted of a Waters model 600E System Controller, Waters model Tunable Absorbance Detector 486, Waters model 717 Autosampler, and an analytical column Inertsil ODS-3 (150ϫ4.6 mm I.D., GL Sciences Inc., Tokyo, Japan) equipped with an Inertsil ODS-3 cartridge (5ϫ4.6 mm). The UV-detector was set at 268 nm. The mobile phase consisted of 20 mM phosphate buffer (pH 3.0) containing 5 mM triethylamine/acetonitrile (88 : 12), and the flow rate was 1 ml/min. The retention time of N-acetylprocainamide was 18 min.
Assay for Procainamide Hydrolase Activity The incubation mixture consisted of 0.5 to 100 mM procainamide, microsomes or cytosol (0.5 mg protein/ml) from human liver or intestine, and 100 mM Tris-HCl buffer (pH 7.4) in a final volume of 500 ml. After preincubation at 37°C for 3 min, the reaction was started by adding procainamide and the mixture was incubated at 37°C for 15 min. The reaction was terminated by adding 200 ml of acetonitrile, and the mixture was centrifuged at 12000ϫg for 3 min. The supernatant (20 ml) was injected into the HPLC, and the concentration of paminobenzoic acid analyzed. The same HPLC system and columns as described above were used, except that the UVdetector was set at 280 nm. The mobile phase consisted of 50 mM acetic acid/methanol (92 : 8), and the flow rate was 1 ml/min. The retention time of p-aminobenzoic acid was 13 min.
Data Analysis All data were analyzed using the average of duplicate determinations. In preliminary experiments, the linearity of the reaction with incubation time and protein concentration was confirmed under each assay condition. Apparent kinetic parameters in pooled human cytosol or microsomes were estimated by fitting to Michaelis-Menten kinetics by nonlinear regression analysis (MULTI), 18) and intrinsic metabolic clearance (CL int ) was calculated as a ratio of V max to K m . For the calculation of CL int (ml/min/g liver), we used the following parameters: the microsomal and cytosolic protein contents in human liver were assumed to be 21.4 and 59.9 mg/g organ, respectively, as reported by Temellini et al. 19) The coefficient of determination (r 2 ) for enzyme activities was determined by linear regression analysis using a software program SAS (SAS Institute Inc, Cary, NC, U.S.A.). Statistical differences between males and females were determined by Student's t-test. The significant level was set at pϽ0.05.
RESULTS
5-Fluorouracil and Procainamide Metabolism by
Human Liver Microsomes and Cytosol Apparent kinetic parameters for the metabolism of 5-fluorouracil and procainamide in microsomes or cytosol from human liver are summarized in Table 1 . The K m values in the 5-fluorouracil metabolism, procainamide N-acetylation, and procainamide hydrolysis were 3.9, 1670, and 969 mM, respectively, and the V max values were 493, 321, and 5.71 pmol/min/mg protein, respectively. The CL int (ml/min/g liver) in procainamide Nacetylation was 33-fold higher than that in procainamide hydrolysis. The activity of procainamide hydrolysis at 2 mM substrate concentration in liver cytosol or intestinal microsomes was less than 2 pmol/min/mg protein (data not shown), suggesting minor importance in the procainamide metabolism.
Interindividual Variability of 5-Fluorouracil and Procainamide Metabolism The interindividual variability of 5-fluorouracil metabolism in 21 liver cytosol specimens is shown in Fig. 1 . The DPD activities of 5-fluorouracil ranged from 145 to 790 (469Ϯ156, meanϮS.D.) pmol/min/mg protein, and there were no significant age-or gender-related differences in the activity.
The procainamide N-acetylation activities in 12 human liver cytosol samples are shown in Fig. 2 . The procainamide N-acetylation activity ranged from Ͻ1 to 152 (52Ϯ48, meanϮS.D.) pmol/min/mg protein, and large interindividual differences were observed. Although slight age-dependency was observed (r 2 ϭ0.412, pϽ0.05), the number of liver samples investigated (nϭ12) might be insufficient for estimating the effect of age on the metabolic activity.
The correlations between procainamide N-acetylation, sulfamethazine N-acetylation, and 5-flurouracil metabolism by human liver cytosol are shown in Fig. 3 . Procainamide Nacetylation was significantly correlated with sulfamethazine N-acetylation (nϭ12, r 2 ϭ0.756, pϽ0.001), whereas no significant correlation was observed between 5-fluorouracil metabolism and procainamide N-acetylation (nϭ12, r 2 ϭ0.0468, pϾ0.05).
DISCUSSION
Although the K m value in the procainamide N-acetylation in pooled liver cytosol was comparable with that in the hydrolysis of procainamide in pooled liver microsomes, the CL int (ml/min/g liver) in procainamide N-acetylation was 33-fold higher than that in procainamide hydrolysis ( Table 1 ), suggesting that the N-acetylation is the most important metabolic pathway for procainamide in human liver. Giardina et al. 20) reported that 31-56%, 7-24%, and less than 0.2% of the dose were excreted as procainamide, N-acetylprocainamide, and p-aminobenzoic acid, respectively, in 24 h after a single oral dosing of 14 C-labeled procainamide to patients with cardiac disease. Therefore, the results of the present in vitro study, using human liver microsomes and cytosol, are consistent with the in vivo clinical studies, which demonstrated that N-acetylprocainamide is a predominant metabolite after oral dosing of procainamide to humans, whereas hydrolyzed metabolites such as p-aminobenzoic acid are minor metabolites. 20) Recently, human hepatocytes, containing both microsomal and cytosolic enzymes, were reported to be useful for the prediction of hepatic clearance of compounds, which are metabolized through several kinds of metabolic pathways, including phase I and phase II reactions. 9, 21) Further studies using hepatocytes might be required to improve the quantitative prediction of the hepatic clearance.
We have demonstrated that there is more than a 152-fold difference among individuals in the activities of procainamide N-acetylation in human liver cytosol (Fig. 2) . In addition, the absence of a significant correlation between 5- (Fig. 3) , and these results provide support indicating that both procainamide and sulfamethazine are metabolized by N-acetyltransferase-2 (NAT2), 22) whose activity is polymorphic. 23) In this study, we could not evaluate the possible contribution of NAT2 polymorphisms to variability in catalytic activity of procainamide N-acetylation, because we could not obtain the genotype information of the liver donors. Correlations between acetylation phenotypes and NAT2* genotypes have been described for isoniazid, sulfamethazine, and caffeine. 23) Although there are few reports describing the relationship between procainamide acetylation activity and NAT2* genotypes, Okumura et al. 23) reported that the N-acetylprocainamide/procainamide ratio in urinary excretion after an oral dose of procainamide hydrochloride was the highest in NAT2*4/*4 genotype followed by NAT2*4/*6A, NAT2*4/*7BϾNAT2* 6A/*7B. It is possible to speculate that genetic factors, as well as environmental factors, may be major contributors.
This study showed that there are neither gender-related nor age-dependent differences in the metabolic activities of 5-fluorouracil in human liver cytosol, with a 5-fold difference among individuals (Fig. 1) . It was observed in previous studies that there are marked (more than 3-fold) interindividual differences in the pharmacokinetics of 5-fluorouracil in cancer patients following intravenous or oral administration of 5-fluorouracil. 12, 24) In addition, 5-fluorouracil is mainly eliminated by metabolism by DPD. 12, 25) Recently, it has been reported that a partial deficiency of DPD in a patient results in a 2.5 fold reduction in 5-fluorouracil clearance. 26) Therefore, these results suggest that, although factors, that could affect oral clearance of a drug, include absorption from the gastrointestinal tract, protein binding, intrinsic hepatic clearance, hepatic blood flow, and renal clearance, the interindividual differences of metabolism may be major contributors to the interindividual variations of 5-fluorouracil pharmacokinetics. In addition, it has been demonstrated that at least 3% of the general population could be partially deficient in DPD activity based on a population analysis of DPD activity. 27) Genetic and environmental factors seem to contribute to the interindividual variation in the activity of 5-fluorouracil, but the regulation mechanism in human liver is still unknown.
In summary, this study has suggested that N-acetylation is the major metabolic pathway of procainamide in human liver, and that there are large interindividual differences in the enzyme activities towards the respective metabolic pathways of 5-fluorouracil and procainamide. It is speculated that genetic regulatory variations, including polymorphism such as DPD and N-acetyltransferase, and environmental factors may be major contributors to the interindividual variations.
